Gilead Sciences, an American biopharmaceutical company, completed the acquisition of MiroBio, a biotechnology company focused on restoring immune balance with agonists targeting immune inhibitory receptors, from Monograph, a fund manager, for $405m. “We are excited to be joining Gilead. MiroBio has a deep understanding of checkpoint receptor signaling and a proprietary approach to select and generate superior agonist antibodies. Combining this with Gilead’s drug development and therapeutic area expertise will allow us to fully explore the potential of checkpoint agonist antibodies for patients with autoimmune disease," Eliot Charles, MiroBio Chairman.